Opendata, web and dolomites

PROSKit SIGNED

Prostate cancer urinary diagnostic kit based on RNA biomarkers

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PROSKit project word cloud

Explore the words cloud of the PROSKit project. It provides you a very rough idea of what is the project "PROSKit" about.

throughput    certify    business    diagnostic    diagnosis    positive    market    urine    collection    samples    poc    home    reduce    specialized    rna    thousands    clinical    analysed    nucleic    anywhere    gt    location    lab    biomarker    billion    biopsy    stabilization    false    holdings    molecular    simultaneously    unnecessary    28    core    invasively    days    specificity    lt    sampling    collect    validate    cancer    prostate    platform    85    point    mix    pca3    tested    ready    14    validated    biotechnology    license    discriminative    assay    protocol    psa    2025    care    extend    environment    price    tests    room    blood    intact    proskit    acids    revenues    stabilise    11    offers    amplifiable    validation    laboratory    minutes    device    surgery    arcis    60    biomarkers    patented    10    kits    proprietary    stability    respect    central    hours    inexpensive    sensitivity    unstable    preparation    competitors    patient    biopsies    tools    weeks    dna    perform    chemicals    segment    requiring    patients    proposing    collected    temperature    rapid    capability    preserving    informative    accurate   

Project "PROSKit" data sheet

The following table provides information about the project.

Coordinator
ARCIS BIOTECHNOLOGY HOLDINGS LIMITED 

Organization address
address: SUITE F42, THE INNOVATION CENTRE KECKWICK LANE
city: DARESBURY WARRINGTON
postcode: WA4 4FS
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2020-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ARCIS BIOTECHNOLOGY HOLDINGS LIMITED UK (DARESBURY WARRINGTON) coordinator 50˙000.00

Map

 Project objective

Arcis Biotechnology Holdings developed and patented PROSKit, a molecular diagnostic platform for the diagnosis of prostate cancer based on urine analysis, able to reduce the number of false positive from the PSA test and so the number of unnecessary biopsies. PROSKit is a proprietary mix of chemicals, that can stabilise nucleic acids (RNA/DNA) in urine for up to 2 weeks at room temperature and then allow sampling at home or Point of Care (PoC) using a patient-friendly sample collection technology, preserving unstable RNA biomarkers and analysis in specialized clinical environment through the PCA3 biomarker. With respect to current diagnostic methods (PSA biopsy), PROSKit offers i) Rapid- samples ready for analysis in <3 minutes, results in <2 hours if tested at surgery, compared to days for biopsy, ii) Accurate- greater sensitivity and specificity than current PSA blood test: PCA3 presents a 28% higher discriminative capability than PSA; iii) Inexpensive- as informative as multi-core biopsy for <10% of the price; iv) High throughput- PROSKit samples can be collected anywhere, non-invasively and thousands analysed simultaneously at a central location. Compared to competitors proposing RNA stabilization requiring laboratory analyses, complex procedures and specific tools, PROSKit offers stabilization at room temperature and with no lab equipment in 3 minutes. Intact amplifiable RNA biomarkers have already been validated for 7 days stability but needs to extend validation for >14 days, validate the protocol for patients to collect urine and analysts to perform assay; certify design of PROSKit device and cost for the device and define agreement with partners for distribution and license for execution of tests. DNA/RNA Sample preparation business market revenues are expected to reach 1.85 billion € in 2025. Kits segment represents 60% of the market: 1.11 billion € in 2025.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROSKIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROSKIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More